Loading…
Akebia Therapeutics, Inc. is projected to rise to $1.73 by 2027, a +23% move from its current price of $1.40. AKBA is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $1.35 | $1.40 | $1.45 | +0.09% |
| Jul 15 | $1.34 | $1.40 | $1.47 | +0.17% |
| Jul 16 | $1.32 | $1.40 | $1.49 | +0.26% |
| Jul 17 | $1.31 | $1.40 | $1.50 | +0.34% |
| Jul 18 | $1.30 | $1.41 | $1.52 | +0.43% |
| Jul 19 | $1.29 | $1.41 | $1.53 | +0.52% |
| Jul 20 | $1.29 | $1.41 | $1.54 | +0.60% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.29 | $1.41 | $1.54 | +0.60% |
| Week 2 | $1.25 | $1.42 | $1.61 | +1.21% |
| Week 3 | $1.22 | $1.43 | $1.67 | +1.82% |
| Week 4 | $1.20 | $1.43 | $1.72 | +2.44% |
| Week 5 | $1.18 | $1.44 | $1.77 | +3.06% |
| Week 6 | $1.16 | $1.45 | $1.81 | +3.68% |
| Week 7 | $1.15 | $1.46 | $1.86 | +4.31% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Akebia Therapeutics, Inc. is a biopharmaceutical company that focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), for the treatment of anemia due to chronic kidney disease in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD.
The company is also developing AKB-9090, in Phase 2 clinical trial for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. It has license and collaboration agreements with Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries; Vafseo License and Collaboration Agreements; CSL Vifor Agreements; Averoa License Agreement; License Agreement with Panion & BF Biotech, Inc.; Cyclerion Therapeutics License Agreement; and Q32 Asset Purchase Agreement. Akebia Therapeutics, Inc.
was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Akebia Therapeutics, Inc. trades as a health care stock in the biopharmaceuticals space. The current price is $1.42 per share, and the company has a market cap of $380.93M with a rank of 3276.
The stock’s price outlook in the forecast horizon shows a path higher, with 2026 avg $1.42, 2027 avg $1.74, 2028 avg $2.15, 2029 avg $2.32, 2030 avg $2.39, 2031 avg $3.54, 2032 avg $4.34, 2033 avg $4.60, 2034 avg $5.14, 2035 avg $5.12, 2040 avg $9.92, and 2050 avg $18.76. The max forecast reaches $38.84 by 2050, with ROI in that year at 1221.2 and sentiment labeled BULLISH. The 2026 forecast is neutral with min $0.873, avg $1.42, max $2.10 and ROI 0.
From 2027 onward the outlook is bullish, with rising averages and substantial upside potential through 2050, albeit with uncertainty inherent in any forecast.
A major floor 51.6% below — a decisive break under it would weaken the trend.
The nearest floor, 37.6% below — buyers have tended to step in here.
Price is pressing into resistance (2.1% away) — a breakout level to watch.
A major ceiling 28.0% above — clearing it would confirm fresh momentum.
Key AKBA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of AKBA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.38 | Buy | $1.37 | Buy |
| MA 10 | $1.27 | Buy | $1.29 | Buy |
| MA 20 | $1.14 | Buy | $1.20 | Buy |
| MA 50 | $1.12 | Buy | $1.17 | Buy |
| MA 100 | $1.24 | Buy | $1.28 | Buy |
| MA 200 | $1.59 | Sell | $1.56 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 71.91 | Sell |
| Stoch RSI (14) | 84.28 | Sell |
| CCI (20) | 126.21 | Buy |
| Williams %R (14) | -7.69 | Info |
| MACD (12,26,9) | 0.04 | Buy |
| ROC (12) | 27.27 | Buy |
| Bollinger %B (20,2) | 0.89 | Neutral |
| Stochastic %K (14) | 92.31 | Sell |
| TRIX (15) | 0.63 | Buy |
| Awesome (5,34) | 0.31 | Buy |
| Ultimate (7,14,28) | 84.24 | Sell |
| Momentum (10) | 0.36 | Buy |
| Aroon Osc (25) | 76.00 | Buy |
| Hull MA (9) | 1.47 | Sell |
| ADX (14) | 28.50 | Buy |
| ATR (14) | 0.04 | Info |
The 30-day technical picture for AKBA is bullish, with RSI14 at 80. The stock trades near the 50-day simple moving average of $1.12 and sits below the 200-day simple moving average at $1.60. A key near-term resistance is at $1.42, which also matches the current price, while the next support level is at $0.873.
The 30-day price range runs from $1.12 to $1.80, highlighting limited upside room in the near term and potential for reactions around the resistance level. Annualized volatility is high at 70%, underscoring elevated risk alongside the bullish setup.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.873 | $1.40 | $2.06 | 0% | Neutral | |
| $1.34 | $1.73 | $2.37 | +23% | Bullish | |
| $1.61 | $2.14 | $3.08 | +53% | Bullish | |
| $1.71 | $2.35 | $3.49 | +68% | Bullish | |
| $1.74 | $2.45 | $3.75 | +75% | Bullish | |
| $2.48 | $3.58 | $5.62 | +156% | Bullish | |
| $2.98 | $4.41 | $7.08 | +215% | Bullish | |
| $3.11 | $4.70 | $7.70 | +236% | Bullish | |
| $3.40 | $5.24 | $8.75 | +275% | Bullish | |
| $3.37 | $5.31 | $9.01 | +279% | Bullish | |
| $5.93 | $10.23 | $18.67 | +631% | Bullish | |
| $9.77 | $19.87 | $40.22 | +13.2x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.873 | $1.40 | $1.75 | +0.00% |
| August 2026 | $1.28 | $1.53 | $1.87 | +9.01% |
| September 2026 | $1.26 | $1.51 | $1.88 | -0.78% |
| October 2026 | $1.26 | $1.52 | $1.91 | +0.16% |
| November 2026 | $1.30 | $1.58 | $2.01 | +4.33% |
| December 2026 | $1.31 | $1.61 | $2.06 | +1.57% |
Click any year to see its month-by-month AKBA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Akebia Therapeutics, Inc.'s 2026 outlook centres on $1.40, within a $0.873 to $2.06 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, AKBA could reach as high as $2.37, with a base case around $1.73 and support toward $1.34 — roughly +23% from $1.40. Buyers look set to stay in control over this stretch.
Expect AKBA to range from $1.61 to $3.08 through 2028. The $2.14 average target implies a +53% move from current prices. That is up +24% on the projected 2027 average. Momentum favours further upside here.
The AKBA price prediction for 2029 points to an average of $2.35 (low $1.71, high $3.49) — a potential gain of +68% on today's $1.40. Buyers look set to stay in control over this stretch.
In 2030, AKBA is projected to trade between $1.74 and $3.75, averaging $2.45 — a potential gain of +75% from today's $1.40. That is up +4% on the projected 2029 average. Momentum favours further upside here.
Akebia Therapeutics, Inc.'s 2031 outlook centres on $3.58, within a $2.48 to $5.62 range. That is up +46% on the projected 2030 average. That marks a +156% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, AKBA could reach as high as $7.08, with a base case around $4.41 and support toward $2.98 — roughly +215% from $1.40. Momentum favours further upside here.
Expect AKBA to range from $3.11 to $7.70 through 2033. The $4.70 average target implies a +236% move from current prices. That is up +7% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The AKBA price prediction for 2034 points to an average of $5.24 (low $3.40, high $8.75) — a potential gain of +275% on today's $1.40. Momentum favours further upside here.
In 2035, AKBA is projected to trade between $3.37 and $9.01, averaging $5.31 — a potential gain of +279% from today's $1.40. That is up +1% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Akebia Therapeutics, Inc.'s 2040 outlook centres on $10.23, within a $5.93 to $18.67 range. That is up +93% on the projected 2035 average. That marks a +631% change versus current levels. Momentum favours further upside here.
By 2050, AKBA could reach as high as $40.22, with a base case around $19.87 and support toward $9.77 — roughly +13.2x from $1.40. Buyers look set to stay in control over this stretch.
Investing $1,000 in AKBA today (≈ 714.285714 AKBA) could be worth
$14,192.06
+$13,192.06 (+1319%) by 2050 · US Dollar
Based on the average projected AKBA price of $19.87 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in AKBAwould be worth at today's price.
$1,000 invested in AKBA on Jul 10, 2025 (≈ 251.25628 AKBA) would be worth
$351.76
-$648.24 (-64.8%) today · 0.35× · US Dollar
Based on a AKBA entry price of $3.98 vs. today's $1.4.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.24 | $1,129.03 | +12.9% |
| 1 month ago | $0.873 | $1,603.67 | +60.4% |
| 3 months ago | $1.4 | $1,000 | +0.0% |
| 6 months ago | $1.4 | $1,000 | +0.0% |
| 1 year ago | $3.98 | $351.76 | -64.8% |
| All time (5.0y) ago | $3.54 | $395.48 | -60.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our AKBA forecast.
Our base-case forecast reaches $2.80 around 2031.
Implied market cap at $2.80: $751.12M
The multi-year forecast shows a gradually rising path from a 2026 average of $1.42 to a 2050 average of $18.76, with interpolated years delivering progressively stronger upside. Notable milestones include 2027 avg $1.74, 2028 avg $2.15, 2029 avg $2.32, 2030 avg $2.39, 2031 avg $3.54, 2032 avg $4.34, 2033 avg $4.60, 2034 avg $5.14, and 2035 avg $5.12. By 2040 the average reaches $9.92, and by 2050 it reaches $18.76.
Max forecasts rise from $2.10 in 2026 to $38.84 in 2050, with corresponding ROI figures climbing to 68.3 in 2030, 149.5 in 2031, 205.4 in 2032, 223.6 in 2033, 261.7 in 2034, 260.8 in 2035, 598.3 in 2040, and 1221.2 in 2050. Sentiment is bullish for the later years, following a neutral start in 2026. These are estimates and not guarantees; actual results may differ, and the long-run upside comes with uncertainty given market dynamics and clinical development outcomes.
Tap a question to reveal the answer.
2030 min $1.67, avg $2.39, max $3.70; ROI 68.3; sentiment BULLISH.
Forecasts show a bullish path from 2027 onward, with 2027 avg $1.74, 2028 avg $2.15, 2030 avg $2.39, and 2050 avg $18.76 with ROI up to 1221.2. These are estimates, not guarantees.
Yes. The forecast shows 2034 max $8.71 and 2035 max $8.85, with 2034 avg $5.14 and 2035 avg $5.12.
Current price is $1.42 per share and market cap is $380.93M.
2040 avg $9.92; max $18.45; ROI 598.3; sentiment BULLISH. 2050 avg $18.76; max $38.84; ROI 1221.2; sentiment BULLISH.
Akebia Therapeutics, Inc. Community Discussion
0Share your Akebia Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.